Description

Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).

Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).

---

Transfection Reagent for LoVo Cells (Colon Adenocarcinoma Cells, CCL-229)

• Two component formulation enhances lipid mediated transfection efficiency
• Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
• Reproducible transfection results
• Works well for standard reverse transfection and high-throughput applications
• Download in vitro LoVo transfection protocol: [PDF]
• Download LoVo CRISPR/Cas9 transfection protocol: [PDF]
• Download PowerPoint presentation for LoVo cells transfection kit: [PPT]
• Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 94% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems LoVo Transfection Protocol: [PDF]

Download MSDS: [PDF]

LoVo Cell Line:

Colorectal cancer is the third most commonly detected cancer in the United States, reportedly accounting for nearly 50,000 fatalities annually, as per the American Cancer Society (ACS). The LoVo epithelial cell line was isolated in 1971 from a metastatic tumor of a 56-year-old Caucasian male with colorectal adenocarcinoma. LoVo cells express multiple oncogenes, including N-ras, H-ras, Myb, c-myc, K-ras, sis and fos genes. Also, CC-3 and CC-4 tumor-specific nuclear matrix proteins are expressed. However, the cells are negative for expression of colon antigen 3 and CSAp (CSAp-). The LoVo cell line presents an aneuploid karyotype with a modal number of 49 and a doubling time of approximately 37 hours. A broad range of LoVo cells shows an extra B chromosome as well as altered A2. The LoVo cell line is a suitable host for studying various types of colon cancer. Altogen Biosystems provides highly efficient transfection reagent kits for the LoVo cell line.

Data:

Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into LoVo cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).

Figure 2. Protein expression of Lamin A in LoVo cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into LoVo cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Selected LoVo transfection reagent citations:

• Carcinogenesis. 2014. A mechanistic study of the proapoptotic effect of tolfenamic acid … Jeong et al [PDF]
• Diabetologia. 2012 55(7):2069-79. The p47phox- and NADPH oxidase organiser 1 … Youn et al [PDF]

Altogen Biosystems:
Altogen Biosystems transfection and electroporation products for life sciences and cancer research. Company developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery to liver, pancreas, and kidney tissues), and broad range in vivo delivery reagents (PEG-Liposome, Nanoparticle-based, Lipid-based, and Polymer-based kits).  Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, mRNA, shRNA, siRNA, and other negatively charged molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Research Services:

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

• 0.5 ml (Catalog #6840)
• 1.5 ml (Catalog #6841)
• 1.5 ml CRISPR (Catalog #2167)
• 8.0 ml (Catalog #7057)

Altogen Biosystems是一家开发和制造用于生命科学研究，药物发现和开发的转染试剂盒的生物技术公司。转染试剂盒针对特定癌细胞系和原代细胞培养进行了优化，可将生物分子有效递送到靶组织中。通过先进的试剂配方和优化的转染方案实现体外（癌细胞系）和体内（动物组织靶向试剂、癌细胞系）递送货物分子，包括质粒DNA，各种类型的RNA（mRNA，siRNA，shRNA，microRNA），蛋白质和小分子研究。 Altogen Biosystems全国代理部分产品列表： 货号 产品 规格 价格（美元） 5030       1703 A204 Transfection Reagent (Rhabdomyosarcoma) 0.5ml 170 1704 A204 Transfection Reagent (Rhabdomyosarcoma) 1.5ml 348 窗体顶端 窗体底端   2101 A204 Transfection Reagent (Rhabdomyosarcoma) 1.5ml CRISPR 548 窗体顶端 窗体底端   7018 A204 Transfection Reagent (Rhabdomyosarcoma) 8.0ml 1044 窗体顶端 窗体底端   1167 A375 Cells Transfection Reagent (CRL-1619) 0.5ml 195 1168 A375 Cells Transfection Reagent (CRL-1620) 1.5ml 427 2102 A375 Cells Transfection Reagent (CRL-1621) 1.5ml CRISPR 627 1169 A375 Cells Transfection Reagent (CRL-1622) 8.0ml 1281 5030 Nanoparticle In Vivo Transfection Reagent 0.5 ml - 10 injections  445 5010 LIPID In Vivo Transfection Reagent 0.5 ml - 10 injections 405 5040 PEG-Liposome In Vivo Transfection Reagent 0.5 ml - 10 injections 465 5020 POLYMER In Vivo Transfection Reagent 0.5 ml - 10 injections 425 5050 Pancreas In Vivo Transfection Kit 0.5 ml - 10 injections  495 5060 Liver In Vivo Transfection Kit 0.5 ml - 10 injections  495 5070 Kidney In Vivo Transfection Kit 0.5 ml - 10 injections  495 1721 BMS2 Transfection Reagent (Bone Marrow Cells) 0.5 ml  231 6345 C6 Transfection Reagent (Glioma Cells, CCL-107) 0.5 ml  199 6803 DLD-1 Transfection Reagent (Colon Cancer, CCL-221) 0.5 ml  201 1775 HUH-7 Transfection Reagent (Liver Cancer Cells) 0.5 ml  179